Would you ever hold off consolidation durvalumab in NSCLC stage III after chemoradiation if KRAS G12C mutation positive given recent concerns for toxicity with IO + sotorasib?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Roswell Park Comprehensive Cancer Center
Answered on
Depends on the PD-L1 status/co-mutations: If PD-L1 0% or with STK11 co-mutation, will not administer durvalumab.
Join for free or sign in to see the full answer